Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES)

Conditions:Arthritis, Osteoarthritis (OA)
Therapuetic Areas:Rheumatology
Age Range:40 - 70
Start Date:March 28, 2019
End Date:December 31, 2021
Contact:Kenneth Mautner, MD

Use our guide to learn which trials are right for you!

Randomized Multicenter Phase 3 Single-blind Trial Comparing the Efficacy of Corticosteroid Control to Mesenchymal Stem Cell Preparations From Autologous Bone Marrow Concentrate (BMAC), Adipose-derived Stem Cells in the Form of Stromal Vascular Fraction (SVF), and Third-party Human Mesenchymal Stem Cells Manufactured From Umbilical Cord Tissue for the Treatment of Unilateral Knee Osteoarthritis (OA)

The study is a multicenter trial conducted to compare the effectiveness of corticosteroid
control to mesenchymal stem cell preparations from autologous bone marrow concentrate (BMAC),
adipose derived stem cells in the form of Stromal Vascular Fraction (SVF), and third party
human mesenchymal stem cells manufactured from umbilical cord tissue (UCT) for the treatment
of unilateral Knee Osteoarthritis (OA). The study will be conducted in 4 sites in the United
States, including Emory University. A total of 480 participants will be enrolled in this

Primary osteoarthritis is a debilitating disease characterized by extensive damage to the
joints and excruciating pain leading to loss of activity and depression. Despite advances in
diagnosis and relatively efficient control of nociception, to date, the quest for the
development of a disease modifying osteoarthritis drug has proven unsuccessful. The potential
of mesenchymal stem cells to inhibit inflammation while promoting healing makes them amenable
for the treatment of various ailments ranging from cancer to genetic diseases. In orthopedic
practice, autologous stem cell injections are performed to alleviate the pain associated with
osteoarthritis. A serious gap in knowledge remains whether the currently used cellular
treatments are beneficial in the long term and if one cell therapy outperforms another.

The most popular form of Autologous Mesenchymal Stem Cells (MSC's) therapy has been through
the use of Autologous Bone Marrow Concentrate (BMAC). The rationale is that when a sample of
Bone Marrow Aspirate (BMA) is collected and the components that are not beneficial to the
joint are filtered out (i.e. red blood cells, neutrophils, etc.) the remaining concentrate
(MSC's, platelets, interleukins, etc) can have a "healing" effect on the environment in which
it is injected. However it is still unknown as to how effective BMAC is for treating
orthopedic conditions compared to other MSC procedures and the most important components of
the BMAC mixture that could aid patients suffering from osteoarthritis.

Adipose tissue has been found to have a large amount of mesenchymal stem cells versus that in
bone marrow. These cells are currently being used in a variety of clinical research studies
within the regenerative medicine field. Through a tissue process which includes washing and
centrifuging, the cellular components can be extracted as a cell pellet, which is also known
as Stromal Vascular Fraction (SVF). Adipose derived SVF is obtained via liposuction, or the
removal of adipose tissue via a suction method.

Although the use of various stem cell preparations for knee osteoarthritis has become
increasingly prevalent, well-designed studies with conclusive proof of comparative
effectiveness and identification of the optimal cell source and "dose" have not been
performed. This study is the first randomized study comparing three types of cellular
treatments to corticosteroids. The main objective of the study is to identify a superior
source of stem cells for the treatment of osteoarthritis and validate its advantages over
corticosteroid injections as the traditional gold standard treatment.

Inclusion Criteria:

- Age >40 but <70 years old

- Males and females

- Recent knee radiograph of the targeted knee (standing AP lateral and sunrise view)

- Diagnosis of OA in the targeted knee (radiographic evidence of OA in the medial and/or
lateral tibiofemoral compartment, which would include one or more osteophytes on a
standard radiograph taken within 3 months)

- Continued OA pain in the targeted knee despite conservative measures (per treating
provider's discretion)

- Average daily VAS ≥3

- Kellgren-Lawrence system of Grade II, III, or IV

- Subjects may have concomitant patellofemoral but they must have stage II or higher
generalized knee OA

- Females of childbearing potential only, must have a negative pregnancy test done ≤ 7
days prior to enrollment in the study

- Women and men of child-producing potential must agree to use acceptable contraception
methods for the duration of the trial such as birth control pills or condoms with

Exclusion Criteria:

- Clinically apparent tense effusion of the targeted knee

- Significant valgus/varus deformities (+/- 5 degrees)

- Viscosupplementation within 6 months in the targeted knee

- Other biologic injection (PRP or stem cell) within 1 year in the targeted knee

- Surgery in the targeted knee within the past 6 months (either open or scope)

- Systemic or intra-articular injection of corticosteroids in any joint within 3 months
before screening

- Daily opioid use for the past three months

- History of malignancy in the previous 5 years prior to study entry, with the exception
of in-situ cancers treated only by local excision with curative intent

- History of, or ongoing, autoimmune disorder that requires treatment with an
immunosuppressive medication

- Active, suspected, or prior infection to the joint in the targeted knee

- Part of a vulnerable population per OHRP definition (pregnant women and breast-feeding
women, cognitively impaired, prisoners, etc.)

- Use of NSAIDS within 1 week of the procedure

- Unwilling to discontinue use of NSAIDS for 5 calendar days after procedure

- History of bleeding disorders or inflammatory joint disease

- Inability to hold anti-platelet therapy according to treating provider prior to

- If deemed medically inappropriate or noncompliant by the treating investigator

- Uncontrolled diabetes

- Subject has an active workers' compensation case in progress

- Subject with insufficient amount of subcutaneous tissue to allow recovery of a minimum
of 100 mL of lipoaspirate

- Hemoglobin less than 10g/dL at the time of screening

- Leukocytes <3,000/μL; neutrophils <1,500/μL; lymphocytes <800/μL; platelets
<100,000/μL at the time of screening

- Diagnosis of liver disease as defined by alanine aminotransferase (ALT) >3x the upper
limit of age-determined normal (ULN) or total bilirubin > 1.5x ULN

- Subjects who have had greater than 3 corticosteroid injections in the targeted knee in
the 12 months prior to screening and at the physician's discretion

- Subjects with a known diagnosis of osteoporosis

- Subjects with anticipated use of systemic corticosteroids during the study period for
treatment of a chronic medical condition
We found this trial at
Atlanta, Georgia 30322
Phone: 404-778-7142
Atlanta, GA
Click here to add this to my saved trials
Durham, North Carolina 27710
(919) 684-8111
Phone: 919-681-9525
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
Durham, NC
Click here to add this to my saved trials
Fargo, North Dakota 58122
Phone: 605-312-6020
Fargo, ND
Click here to add this to my saved trials
Gulf Breeze, Florida 32561
Phone: 850-916-8783
Gulf Breeze, FL
Click here to add this to my saved trials
Sioux Falls, South Dakota 57104
Phone: 605-312-6020
Sioux Falls, SD
Click here to add this to my saved trials